Global Prostate Cancer

Global Prostate Cancer Market Research Report: Forecast (2022-27)

By Diagnosis (Tissue Biopsy, Transrectal Ultrasound, Prostate-specific Antigen Testing, Urine Testing, Imaging), By Treatment (Surgery (Radical Prostatectomy, Cryotherapy, Orchiectomy (Surgical Castra Read more

  • Healthcare
  • Jun 2022
  • 185
  • HC22090

Market Definition

The prostate is a part of the male reproductive system, located below the bladder & in front of the rectum, surrounding the urethra. The prostate gland produces fluid, making a part of semen. When cells in the prostate multiply uncontrollably, it is said to be prostate cancer, whose early stages are usually asymptomatic, and the later stages, however, can display a few signs like:

  • Blood in the urine or semen
  • Bone pain
  • Erectile dysfunction
  • Reduced stream flow of urine
  • Trouble in urination
  • Weight loss without trying

As common as prostate cancer is becoming, the demand for its effective diagnosis & treatment is rapidly rising & instigating various companies to produce novel drugs concentrating on unmet patient needs. Ongoing developments of novel therapeutics for prostate cancer are expected to offer improved survival time, less toxicity, better progression-free survival, effectiveness, & greater affordability for the patient.

Market Insights

The Global Prostate Cancer Market is projected to grow at a CAGR of around 10.8% during the forecast period, i.e., 2022-27. Prostate cancer is one of the most common cancers in males worldwide. With its rising incidence, the demand for effective diagnosis & treatments is also surging rapidly and instigating the governments of different countries to increase their healthcare expenditures.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR 10.8%
Regions Covered North America: The US, Canada, Mexico
Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
South America: Brazil, Rest of Latin America
Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled

Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Others

Unit Denominations USD Million/Billion

 

It, in turn, is demonstrating increasing R&D activities associated with bringing innovations in drugs for prostate cancer therapies and encouraging the leading players to actively participate in the development, production, & distribution of more and more diagnostic equipment & therapeutic medications for patients.

Governments of several countries are spreading awareness about the availability of diagnosis & treatment for prostate cancer through advertisements, campaigns, screening tests, and by conducting & implementing programs for screening tests like Prostate-Specific Antigen (PSA) blood tests & Digital Rectal Exam (DRE) for male patients above 50 years, and other mediums.

It, in turn, is driving the patient pool for prostate cancer worldwide. Favorable policies for clinical trials of medications are instigating the leading biopharma companies to introduce affordable therapeutics. Moreover, the incorporation of technologies like Multiparametric Magnetic Resonance Imaging (mp-MRI) to enhance the identification of tumors & guide if there is a need for tissue biopsy in prostate cancer is also demonstrating increasing diagnosis and augmenting the market expansion. In addition, the approaching patent expiration of various prostate cancer drugs like Zytiga would further generate lucrative opportunities for the leading players in the Global Prostate Cancer Market over the forecast years.

Market Segmentation

Based on Treatment:

  • Surgery
    • Radical Prostatectomy
    • Cryotherapy
    • Orchiectomy (Surgical Castration)
  • Hormone Therapy
    • LHRH (Luteinizing Hormone-Releasing Hormone) Agonists
      • Leuprolide (Lupron, Eligard)
      • Goserelin (Zoladex)
      • Triptorelin (Trelstar)
      • Leuprolide mesylate (Camcevi)
    • LHRH (Luteinizing Hormone-Releasing Hormone) Antagonists
      • Degarelix (Firmagon)
      • Relugolix (Orgovyx)
  • Radiation Therapy
    • External Beam Radiation Therapy (EBRT)
      • Proton Beam Radiation Therapy
      • Three-Dimensional Conformal Radiation Therapy (3D-CRT)
      • Stereotactic Body Radiation Therapy (SBRT)
    • Brachytherapy (Internal Radiation Therapy)
    • Radiopharmaceuticals
  • Chemotherapy
    • Docetaxel (Taxotere)
    • Cabazitaxel (Jevtana)
    • Mitoxantrone (Novantrone)
    • Estramustine (Emcyt)
  • Targeted Therapy
    • Rucaparib (Rubraca)
    • Olaparib (Lynparza)

Of all treatments, surgery is projected to dominate the Global Prostate Cancer Market with the largest share during 2022-27. It is one of the prominent treatment options for prostate cancer, followed by radiation therapy, including proton beam therapy.

Although Chemotherapy, Hormonal therapy, etc., are other treatments, their outcomes vary depending upon the patient's clinical conditions. Healthcare professionals choose surgery as a common treatment for curing prostate cancer in cases where it has not spread outside the prostate gland.

Radical prostatectomy is expected to remain a prominent type of surgery in patients with prostate cancer. It is an operation where the surgeon removes the entire prostate gland and also tissues like seminal vesicles. There are two types of Radical Prostatectomy:

  • Open Prostatectomy
    • Radical Retropubic Prostatectomy
    • Radical Perineal Prostatectomy
  • Laparoscopic Prostatectomy
    • Laparoscopic Radical Prostatectomy
    • Robotic-assisted Laparoscopic Radical Prostatectomy

Open prostatectomy is a surgery in which the surgeon operates through a single long skin incision for the removal of the entire prostate & its nearby tissues. On the other hand, laparoscopic prostatectomy involves multiple incisions and the use of long surgical tools for prostate removal. Among the two, the latter is swiftly gaining momentum and becoming a common approach to prostatectomy and might also offer results similar to the Open Prostatectomy.

On the other hand, radiation therapy is another treatment anticipated to contribute substantially to the expansion of the Global Prostate Cancer Market during 2022-27. It owes principally to the growing inclination toward External Beam Radiation Therapy (EBRT), wherein beams of radiation are focused on the prostate gland to kill cancer cells. This treatment is used extensively on patients with early-stage prostate cancer. The EBRT also helps relieve symptoms like bone pain in case cancer has spread to that area.

Besides, Proton Beam radiation therapy is anticipated to gain significant momentum for the treatment of prostate cancer and propel the overall market growth through 2027. It owes to its high effectiveness on cancer cells by focusing a beam of protons on them, causing little damage to the tissues while passing through, and releasing the energy after traveling a certain distance.

Furthermore, theoretically, proton beams deliver more radiation to the prostate while doing less damage to tissues than other radiation therapies. Although the therapy still requires a lot of development and is not widely available, it shall generate growth prospects for the leading players to indulge in rigorous research & development activities and contribute to the market expansion in the future.

Based on Diagnosis:

  • Tissue Biopsy
  • Transrectal Ultrasound
  • Prostate-specific Antigen Testing
  • Urine Testing
  • Imaging

Prostate cancer was diagnosed traditionally by Digital Rectal Examination (DRE) & Prostate-specific Antigen (PSA) testing, followed by the Transrectal Ultrasound (TRUS) guided biopsy. However, indications from results of PSA remain controversial in patients, as the test is organ-specific and not prostate cancer-specific, which results in fluctuations in results & misdiagnosis. However, in case the results of PSA & DRE suggest signs of prostate cancer, the patient then goes for TRUS, i.e., anticipated to gain swift momentum in the Global Prostate Cancer Market during the forecast period, owing to its fast, convenient, & effective model for diagnosis.

Besides, the growing demand for TRUS is also due to their easy application across hospitals with limited allocations. Furthermore, mounting awareness among patients about the benefits of TRUS biopsy, like lower possibilities of severe complications, is another crucial aspect contributing to the overall expansion of the global prostate cancer market. Yet, further developments in the existing practice are still required to increase the tolerance & reduce the chances of post-biopsy infections.

Regional Landscape

Geographically, the Global Prostate Cancer Market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Among all regions globally, North America is anticipated to contribute significantly to the Prostate Cancer Market growth during 2022-27, principally due to the rapidly increasing patient pool of prostate cancer and the burgeoning need for effective diagnosis & treatments, coupled with the immense support from governments of different countries through substantial investments in the research & development activities for bringing advancements in existing medications & drugs and introducing more effective novel therapies.

Besides, the leading biopharma companies, especially across the US & Canada, conducting clinical trials of new therapeutics for prostate cancer treatment, coupled with rapid drug approvals by the FDA, are other prominent aspects augmenting the growth of the North America Prostate Cancer Market.

On the other hand, Asia-Pacific is anticipated to observe the fastest market growth through 2027. It owes to massive government investments in healthcare infrastructure developments, i.e., demonstrating an increasing number of hospitals, research centers, clinics, specialty centers, etc., across various countries in the region.

As a result, the mounting demand for procuring more & more diagnostic equipment & therapeutic drugs is leading to numerous ongoing R&D activities on bringing innovations in therapeutics to cater to burgeoning patient needs for prostate cancer treatments.

Besides, surging consumer awareness about the availability of affordable diagnosis & treatment for prostate cancer is showcasing a rise in screening tests & diagnoses, i.e., another crucial aspect propelling the regional market growth.

Recent Drug Approvals Associated with Global Prostate Cancer Market

  • In June 2021, Novartis International AG announced receiving approval from the US Food & Drug Administration (FDA) for the Breakthrough Therapy Designation (BTD) to 177Lu-PSMA-617 in patients with conditions of metastatic castration-resistant prostate cancer (mCRPC).
  • In January 2021, the FDA also approved Relugolix (Orgovyx), a new drug that would modify the therapy for advanced prostate cancer, and showed remarkable success in reducing testosterone levels in men with advanced prostate cancer, as found through a massive clinical trial.

Possible Restraint in the Global Prostate Cancer Market

The high costs associated with the tissue biopsy for prostate cancer, especially in cases of advanced-stage tumors, might restrain the fledged expansion of the Global Prostate Cancer Market during 2022-27. Besides, high consultation fees and poor reimbursement of treatment expenditures might also act as significant growth restraints for the market in the coming years.

Key Questions Answered in the Market Research Report:

  1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Prostate Cancer Market?
  2. What are the region-wise industry size, growth drivers, and challenges?
  3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Prostate Cancer Market?
  4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Prostate Cancer Market based on the competitive benchmarking matrix?
  5. What are the key results derived from surveys conducted during the Global Prostate Cancer Market study?

Frequently Asked Questions

A. The Global Prostate Cancer Market is projected to grow at a CAGR of around 10.8% during 2022-27.

A. High costs associated with the diagnosis & treatment of prostate cancer, coupled with difficulties in financial support for patients, are the prominent factors that may hinder the growth of the Global Prostate Cancer Market through 2027.

A. Radiation therapy is anticipated to emerge as an area of remunerative opportunities for the leading players in the Global Prostate Cancer Market over the forecast years.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Prostate Cancer Market Trends & Insights
  4. Global Prostate Cancer Market Regulation & Policy, By Country
  5. Global Prostate Cancer Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Prostate Cancer Market Hotspot and Opportunities
  7. Global Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Tissue Biopsy
        2. Transrectal Ultrasound
        3. Prostate-specific Antigen Testing
        4. Urine Testing
        5. Imaging
      2. By Treatment
        1. Surgery
          1. Radical Prostatectomy
          2. Cryotherapy
          3. Orchiectomy (Surgical Castration)
        2. Hormone Therapy
          1. LHRH (Luteinizing Hormone-Releasing Hormone) Agonists
            1.  Leuprolide (Lupron, Eligard)
            2. Goserelin (Zoladex)
            3. Triptorelin (Trelstar)
            4. Leuprolide mesylate (Camcevi)
          2. LHRH (Luteinizing Hormone-Releasing Hormone) Antagonists
            1. Degarelix (Firmagon)
            2. Relugolix (Orgovyx)
        3. Radiation Therapy
          1. External Beam Radiation Therapy (EBRT)
            1. Proton Beam Radiation Therapy
            2. Three-Dimensional Conformal Radiation Therapy (3D-CRT)
            3. Stereotactic Body Radiation Therapy (SBRT)
          2. Brachytherapy (Internal Radiation Therapy)
          3. Radiopharmaceuticals
        4. Chemotherapy
          1. Docetaxel (Taxotere)
          2. Cabazitaxel (Jevtana)
          3. Mitoxantrone (Novantrone)
          4. Estramustine (Emcyt)
        5. Targeted Therapy
          1. Rucaparib (Rubraca)
          2. Olaparib (Lynparza)
      3. By End-User
        1. Hospitals
        2. Clinics
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Prostate Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia-Pacific
  13. Global Prostate Cancer Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. Abbott Laboratories
      2. AbbVie Inc.
      3. Amgen Inc.
      4. AstraZeneca PLC
      5. Bayer AG
      6. Bristol Myers Squibb
      7. Eisai Co. Ltd.
      8. Eli Lilly and Company
      9. F. Hoffmann-La Roche AG
      10. GlaxoSmithKline PLC
      11. Merck & Co., Inc.
      12. Novartis International AG
      13. Pfizer Inc.
      14. Sanofi S.A.
      15. Others
  15. Disclaimer
 Prostate Cancer Market Segmentation